Uroplakin III Is a Highly Specific and Moderately Sensitive Immunohistochemical Marker for Primary and Metastatic Urothelial Carcinomas

Abstract

Uroplakins are specific differentiation products of terminally differentiated superficial urothelial cells. We tested the value of a new commercially available monoclonal antibody against uroplakin III (clone AU 1) as a paraffin-reactive immunohistochemical marker for primary and metastatic urothelial carcinomas. The study cases included 67 urothelial carcinomas of the urinary tract (35 primary tumors, 32 metastases) and 318 nonurothelial carcinomas, as well as 5 benign Brenner tumors and 2 transitional cell carcinomas of the ovaries. Uroplakin III was detected in 21 (60%) of the primary urothelial carcinomas and 17 (53%) of the metastases, resulting in an overall sensitivity of 0.57. The studied Brenner tumors also were immunoreactive for uroplakin III. All other studied carcinomas were consistently uroplakin III-negative (specificity 1.00). We found the new monoclonal antibody AU 1 against uroplakin III to be a highly specific paraffin-reactive immunohistochemical marker for urothelial tumors with a moderate sensitivity for the identification of primary and metastatic urothelial carcinomas.

Carcinoma Papilar De Células Escamotransicionales Del Cérvix: Presentación De 16 Casos Y Revisión De La Literatura

“…Esto prueba que los carcinomas papilares de células escamotransicionales del cérvix carecen de verdadera diferenciación transicional y probablemente comparten rasgos clínico-patológicos similares con el carcinoma de células escamosas cervical. En estudios previos, la uroplaquina III ha sido detectada, en el 60% de los carcinomas uroteliales primarios y en el 53% de las metástasis, por lo que se considera un marcador con alta especifi cidad pero con sensibilidad moderada para diferenciación celular transicional (35). Aunque la uroplaquina III tiene solamente una modesta sensibilidad como marcador para diferenciación de células transicionales, la falta de inmunoreactividad en casi la totalidad de los casos, soporta una ausencia de verdadera diferenciación de células transicionales en el carcinoma papilar de células escamo-transicionales.…”

High Expression of Human Uroplakin Ia in Urinary Bladder Transitional Cell Carcinoma

“…3,7,8,[14][15][16] However, only a small number of antibodies binding to UP Ia have been reported, and all were generated against bovine UP Ia. 3,14,15) Therefore, to our knowledge, this is the first report of the establishment of an anti-human UP Ia polyclonal antibody.…”

“…Previous reports have described antigen-unmasking treatments including trypsin and microwaves. 7,8,10,[17][18][19][20][21][22] We also used a heating method employing a microwave oven, but could not achieve stronger staining than that with untreated slides (data not shown). In our study, the immunoreactivity of the intermediate layer in urothelium was enhanced by the antigen retrieval technique.…”

“…[4][5][6] Several monoclonal or polyclonal anti-bovine UPs II and III antibodies have been raised, and immunohistochemical studies were performed. [7][8][9][10] The expression of UPs II and III was observed not only in normal transitional cells, but also in TCC. [7][8][9] However, anti-human UP Ia antibodies have not been produced, nor has UP Ia expression been examined in TCC.…”

“…[7][8][9][10] The expression of UPs II and III was observed not only in normal transitional cells, but also in TCC. [7][8][9] However, anti-human UP Ia antibodies have not been produced, nor has UP Ia expression been examined in TCC. Therefore, its clinical usefulness remains unknown.…”